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Summary 
Resistant C57BL/6  mice infected with Leishmania major are self-healing, whereas susceptible 
BALB/c  mice  fail  to  contain  cutaneous  infection  and  subsequently  undergo  fatal  visceral 
dissemination. These disparate outcomes are mediated by dissimilar expansions of T helper type 
1 (Thl) and Th2 CD4 + T  lymphocyte subsets in vivo during cure and progression of disease. 
Because interleukin 12 (IL-12) has potent T  cell growth and interferon 3, (IFN-'),) stimulatory 
effects,  we studied  its  effect on  CD4 §  T  cell  differentiation during  murine  Ieishmaniasis. 
Treatment with recombinant murine (rMu)IL-12 during the first week of infection cured 89% 
of normally susceptible BALB/c mice,  as defined by decreased size  of infected footpads and 
1,000-10,000-fold reduced parasite burdens, and provided durable resistance against reinfection. 
Cure was associated  with markedly depressed production of IL-4 by lymph node cells cultured 
with antigen or mitogen, but preserved or increased production of IFN-3, relative to untreated 
mice. IL-4 and IFN-'y mRNA  associated  with CD4 §  T  lymphocytes isolated from infected 
lymph nodes showed similar reciprocal changes in response to rMulL-12 therapy. A single injection 
of anti-IFN-'), monoclonal antibody abrogated the protective effect of rMulL-12 therapy and 
restored Th2 cytokine responses.  We conclude that rMulL-12 prevents deleterious Th2 T  cell 
responses and promotes curative Thl responses in an IFN-y-dependent fashion during murine 
leishmaniasis. Since BALB/c leishmaniasis cannot be cured with rMulFN-'y alone, additional 
direct effects of IL-12 during T cell subset selection are suggested. Because rMulL-12 is uniquely 
protective in this well-characterized model of chronic parasitism, differences in IL-12 production 
may underlie heterogenous host responses to L.  major and other intracellular pathogens. 
I~ 
ishmania infects vertebrate hosts to cause a spectrum of 
disease ranging from self-limited cutaneous ulceration 
to fatal progressive disease. Healing and progression of rou- 
tine leishmaniasis are causally linked to the dissimilar expan- 
sion of functionally distinct Thl and Th2 CD4 ~ T lympho- 
cyte subsets during infection (1, 2). Thl cells producing IFN-3, 
necessary for control of infection are present in healing tissues, 
whereas progression of disease  is mediated by Th2 CD4 + 
T lymphocytes that produce IL-4 (3-5). The reasons for such 
host-specific differences in CD4 + T  cell differentiation are 
not well understood. Although IFN-3, and IL-4 are each neces- 
sary for the respective expansion of Thl and Th2 cells in vivo 
(4, 6),  a puzzling aspect of BALB/c susceptibility is that it 
is not reversed by treatment with rlFN-y during infection 
(7). Because IL-12 has both T cell growth and IFN-'y stimula- 
tory properties (8, 9), we hypothesized that this factor might 
contribute to the evolution of protective T  cell immunity 
during murine leishmaniasis. 
Materials and Methods 
Mice.  Female  BALB/c and C57BL/6 mice (6 wk old) were pur- 
chased from Charles River Labs. (Wilmington,  MA) and kept in 
the Cleveland Veterans Administration Medical Center animal care 
facility. 
Cytokine and  Antibody Reagents.  The  rat  mAb  XMG1.2 
(anti-routine IFN-'Ir, IgG1) was a gift  from Dr.  T.  Mosmann 
(University of Alberta, Edmonton, Canada) and was grown and 
purified as described (4). Mouse rlL-12 (sp act, 7.8  x  106 U/rag; 
endotoxin, 0.5-0.9 EU/mg) was a gift from Dr. S. Wolf (Genetics 
Institute,  Cambridge, MA). 
Parasite Cultivation and Antigen Preparation.  Leishmania major 
(WHO strain WHOM/IR/-/173)  were grown in M199 containing 
antibiotics, supplemental  glutamine, and 30% FCS (Whittaker Bio- 
products,  Walkersville, MD) as described (10). Stationary-phase 
promastigotes were injected into the hind feet of recipient mice 
at a dose of 2  x  106 organisms/footpad to initiate infection. The 
course of infection was monitored 5}, measuring the thickness of 
footpad swelling weekly using a dial gauge caliper. 
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footpad tissue was minced in 10 ml of M199/30 FCS medium sup- 
plemented with 20 ram Hepes (pH 7.4), crushed through a no. 
200 stainless steel screen, and disrupted using a Tenbroeck homog- 
enizer (Fisher Scientific,  Pittsburgh, PA). 50-/~1 aliquots of footpad 
or lymph  node  suspension were sequentially diluted  fivefold in 
promastigote growth medium, placed into flat-bottomed 96-well 
plates, and incubated at 26~  in humidified room air. Individual 
wells were examined using an inverted microscope at 200x  at 2-d 
intervals for the presence of motile promastigotes. Data represent 
the geometric mean and standard error of the last positive reciprocal 
dilution  for each experimental group. 
RNA Hybridization.  RNA was purified from lymph node tissue 
and lymphocyte subsets as described (1). After electrophoresis in 
a 1% agarose/1.9% formaldehyde denaturing gel, the RNA was 
transferred to nylon membranes and hybridized with 32p-labeled 
antisense RNA probes specific for p35 and p40 Ib12,  Ib4, and 
IFN-'7 (4, 9). 
Generation and Measurement of Lymphokines from Lymph Node Cul- 
ture.  Popliteal  lymph nodes from mice infected for 4 wk with L. 
major and spleens from uninfected mice were disrupted into cel- 
lular suspension at 5  x  106 ceUs/ml in DMEM containing  10% 
FCS, 100 U/ml penicillin, 100/~g/ml streptomycin,  and 2 raM gluta- 
mine. Each specimen was cultured in media alone or in media with 
added Con A (4/zg/ml), stationary phase promastigotes (105/ml), 
or  freeze-thaw  promastigote  antigen  (equivalent of 2  x  106 
promastigotes/ml).  Conditioned media were removed after 48 h, 
centrifuged to remove cellular debris, and stored at 4~  for assay 
within 1 wk and/or frozen for later assay. ELISA techniques and 
reagents for the assay  of routine IFN-3' and Ib4 are as described (5). 
Magnetic  Selection of CD4 + and  CD8 + Lymph  Node  Cells. 
Popliteal lymph  node  cells were  suspended in  Mg  2+/Ca2+-free 
HBSS with 1% FCS added, incubated 30 rain with 10/~g/ml  of 
biotinylated anti-CD4 or anti-CD8 mAb, washed, and gently mixed 
with avidin-coated magnetic beads on a rotary wheal at 4~  (Dy- 
nabeads; Robbins Scientific,  Mountain View, CA). Bead-bound  lym- 
phocytes  were  isolated  using  a  magnetic  separator  (Robbins 
Scientific), washed once, and resuspended in 6 M guanidine HC1 
for RNA extraction. The purity of T calls obtained by this method 
has been consistently 90-95% for CD4 + and 85-90% for CD8 + 
T  cells (4). 
BioassayforlL,12.  BALB/c  and C57BL/6 mice infected  for 3 wk 
received 100/~g of Salmonella enteritidis LPS (Sigma Chemical Co., 
St. Louis, MO) by intraperitoneal injection.  Serially diluted ali- 
quots of serum were incubated for 48 h with naive BALB/c spleno- 
cytes suspended at 107 ceUs/ml in DMEM/10% FCS, and the con- 
ditioned media were assayed for IFN-3~ by ELISA. Units of IL-12 
activity were defined as the reciprocal dilution of serum at which 
half-maximal stimulation of IFN-3, release occurred; recombinant 
murine (rMu)II,-12 was used as an internal standard and positive 
control. Control serum with or without added LPS did not stimu- 
late IFN-% Activity in serum peaked at 4 h after endotoxin injec- 
tion. The presence of IL-12 was confirmed by incubation of serum 
samples in  96-weU culture  plates previously coated with  non- 
neutralizing anti-Mulb12 mAb 5C3 (Richard Chizzonite, Hoff- 
mann-La Roche, Inc.) and subsequent measurement of lympho- 
blast proliferation  induced by the captured cytokine as described  (11). 
Flow Cytometry.  Suspensions of lymph node cells were labeled 
with rat anti-mouse CD4 (GK1.5; American Type Culture Col- 
lection, RockviUe,  MD) and anti-mouse CD8 (53-6.72; American 
Type Culture Collection) mAbs and then with FITC-conjugated 
anti-rat IgG antisera (mouse serum adsorbed; Kirkegaard & Perry 
Laboratories, Inc., Gaithersburg, MD) as previously described (4), 
and analyzed using a FACScan  |  flow cytometer (Becton Dickinson 
& Co.,  Mountain  View, CA). 
Results  and  Discussion 
To demonstrate a functional role for IL-12 in antileishmanial 
immunity, we treated BALB/c mice with mouse rlL-12 given 
by intraperitoneal injection for the first  7  d  of infection. 
Therapy was limited to the first week of infection because 
discrete Thl and Th2 responses first evolve during this time 
(12) and because other therapeutic interventions that act to 
alter CD4 + differentiation, such as treatment with anti-IL-4 
and anti-CD4 mAbs, are only effective if given with 1 wk 
of infection (7, 12, 13). Treatment of BALB/c mice with ei- 
ther 0.2 and 0.5/~g of rMulL-12 markedly reduced footpad 
swelling after cutaneous inoculation with the parasite at that 
site (Fig. 1). This correlated with 1,000-10,000-fold decreases 
in numbers of parasites cultured from homogenized footpad 
and lymph node tissue (Table  1). As defined by decreasing 
footpad size or parasitic burden at 4-5 wk of infection, 16 
of 18 rMulL-12-treated mice healed in comparison with  1 
of 18 untreated mice in three separate experiments (89% vs. 
5.6%; p < 0.05, Fisher exact test). Approximately two-thirds 
of cured mice observed for 4 mo remained free of obvious 
disease  and  were  resistant  to  reinfection  with  2  ￿  106 
stationary-phase promastigotes. 
Lymphocytes obtained from the draining lymph nodes of 
treated mice produced 10-50-fold less IL-4 in response to Con 
A  mitogen and L.  major antigen compared with untreated 
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Figure  1.  The effect  of rMulL-12 on progression of leishmaniasis in 
BALB/c  mice. Footpad  measurements  represent  the mean _+ SEM for four 
mice given either no treatment (O) or seven  daily intraperitoneal  injec- 
tions of 0.2/zg of rMulb12 commencing  with the day of infection  (@). 
Mice cured using rMulL-12 were reinfected  at 12 wk of infection with 
2 x  10  6 promastigotes (arrow) and not further treated with rMulL-12. 
Footpad necrosis  necessitated  euthanasia of control mice at the time indi- 
cated by the asterisk. 
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Exp.  Mice  Footpad*  Lymph  node* 
logjo •  SEM 
1  BALB/c  11.4  +  0.0  9.7  •  1.7 
BALB/c  +  rMulL-12 t  8.2  •  1.3  7.6  ,+  0.9 
2 
BALB/c  6.9  •  0.8  7.2  _+  0.4 
BALB/c  +  rMulL-12*  2.8  _+  0.4  5.9  .+  0.0 
* Geometric mean and SEM of the last positive dilution obtained  from 
0.1 g of footpad  tissue or 2.5  ￿  106 cells of lymph node suspension ob- 
tained  after  4 wk of infection. 
Mice treated  with 0.5/xg of rMulL-12 daily for the first  7 d of in- 
fection. 
mice (Table 2). Indeed, the Con A response was suppressed 
below that obtained from uninfected BALB/c spleen cells. 
IFN-3' production by rMuIL-12-treated mice was variably 
increased, with the mean values similar or greater than that 
of control-infected mice (Table 2). These data are consistent 
with a profound suppression of Th2 development in the treated 
mice, with concomitant sparing or promotion of Thl activity. 
Because IFN-'u production was inconsistently enhanced at 
4 wk of infection in the rMuIL-12-treated mice, we sought 
to determine if the protective effects of rMuIL-12 were IFN-3' 
dependent. A single 1.0-mg dose of anti-IFN-3, mAb XMG1.2 
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Figure  2.  The effect of a single 1.0-mg injection  of anti-IFN-3,  mAb 
XMG.1.2 on the healing of leishmaniasis induced by rMulL-12 in BAI,B/c 
mice. Footpad  measurements  represent  the mean  _+  SEM for four mice 
receiving either no therapy (I-]), seven  daffy  injections of  0.5 #g of rMulL-12 
commencing on the day of infection  (11), or 1.0 mg of XMB1.2  given 
by intraperitoneal  injection on the day of infection in combination with 
7 d of rMulL-12 therapy  (A). Asterisks  denote footpad  necrosis. 
exacerbates leishmaniasis in normally resistant C57BL/6 and 
C3H mice (12). Cotreatment with 1.0 mg of XMG1.2 on 
the day of infection abrogated the protective effect of rMulL-12 
in BALB/c mice, although this exacerbation  was delayed by 
Table  2.  Production  of IFN-  T and IL-4 by Draining Lymph Node Cells 
Cytokine concentration 
Con A  L.  major antigen 
Exp.  IFN-y  IL-4  IFN-3'  IL-4 
1" 
2~ 
ng/ml +_- SEM 
Control  15.4  _+  4.1  36.1  +  8.8  24.3  +  2.6  30.5  •  14.0 
rMulL-12  8.0  +  2.2  3.6  _+  2.0  18.8  _+  16.4  0.6  •  0.2 
Uninfected BALB/c spleen  12.8  +  2.1  41.0  _+  16.9  <0.05  <0.1 
Infected BALB/c  61.5  +  20.8  85.6  _+  25.1  14.13  +  3.6  54.0  •  20.9 
rMulL-12  17.8  _+  6.3  3.5  _+  1.2  32.1  _+  16.8  2.2  •  1.9 
rMulL-12  plus  Anti-IFN-'y mAb  49.8  _+  13.1  72.0  +  18.0  24.49  _+  9.8  62.9  •  25.8 
Suspensions of lymph node cells from mice infected for 4 wk and spleen cells from uninfected  BALB/c mice were cultured for 48 h in the presence 
of 4 #g/ml of Con A, 10S/ml of viable promastigotes  (Exp.  1), or freeze-thawed  antigen equivalent  to 2  x  106 promastigotes/ml (Exp.  2). Condi- 
tioned media were assayed for IL-4 and IFN-T by ELISA. Cells cultured in media alone yielded cytokine levels <20% of that produced  in r~ponse 
to antigen.  Designated BALB/c mice were treated  with 0.5 #g of rMulL-12 for the first 7 d of infection.  Where specified, 1.0 mg of anti-IFN-')' 
mAb (XMG1.2)  was  given as a single dose on the day of infection. 
* n  =  4 mice for control and  treated  mice. 
t n  =  4 for control, 3 for rMulL-12,  and 4 for rMulL-12/anti-IFN-'y-treated mice. 
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that the final curative effect of IL-12 is dependent on IFN-7. 
Draining lymph node cells from mice cotreated with anti- 
IFN-7 showed restored IL-4 production relative to mice treated 
with rMulL-12 alone (Table 2). 
IL-12 is a growth factor for several lymphocyte popula- 
tions,  including NK cells, 7/~ +,  and CD4 +  and CD8 + 
c~/B + T  lymphocytes (14). Although the proportions of 
lymph node cells  that  were  CD4 + ,  CD8 +,  and  surface 
(s)Ig § (B cells) were not significantly altered in rMulL-12- 
treated mice compared with untreated mice during infection 
(34.8  +  12.4 vs. 32.5  +  4.9,  12.4  +_  1.0 vs. 14.9  _+  2.6, 
and 47.5  _+  7.9 vs. 50.6  +  4.1% respectively, for CD4 + , 
CD8 +,  and slg + lymphocytes), IFN-7  generated by the 
lymph node cells of rMulL-12-treated mice may have been 
derived from CD8 + T  lymphocytes or NK cells and not 
from CD4 + Thl cells. Therefore,  RNA was harvested after 
4 wk of infection from draining lymph node populations 
separately enriched for CD4 + , CD8 +,  and slg + lympho- 
cytes or depleted of these subsets (Other) for hybridization 
with IFN-7 and IL-4-specific RNA probes (Fig. 3). Only 
BALB/c  BALB/c 
rMulL-12 
IFN-~  ~  O 
IL-4 
Eth Br 
12345678 
Figure 3.  The relative abundance of IFN-7 and IL-4 mKNA in CD4 + 
and CD8 § T cells in control and rMullc12-treated BALB/c mice during 
infection.  After  4  wk of infection,  populations  enriched  for  CD4 +, 
CDS*, and slg* cells by magnetic bead selection were obtained from the 
popliteal lymph nodes of BALB/c mice with progressive  leishmaniasis  (lanes 
I-4) or from BALB/c mice cured after treatment with 0.5 gg of rMulL-12 
for the first 7 d of infection (lanes 5-8). RNA obtained from lymph node 
cells relatively depleted of CD4 + , CD8 + , and slg + lymphocytes (<6% 
of each) is also included (Other). 15-#g of RNA from each cellular sub- 
population was loaded per lane, except in the fractions labeled Other, which 
received 5 #g. KNA loading was confirmed by ethidium bromide labeling 
of the agarose gel after electrophoresis (Eth Br). 
CD4 + T cells expressed these lymphokine messages during 
infection. IFN-7 expression was increased twofold in rMulL- 
12-treated mice, whereas IL-4 production was dimim'shed four- 
fold as measured by densitometry. Combined with parallel 
changes observed in the production of cytokines by antigen- 
stimulated lymph node cultures (Table 2), these results confirm 
a reversal of Th2 and Thl activities after rMulL-12 therapy. 
The protective effect of rMulL-12 in susceptible BALB/c 
mice suggests that increased production of IL-12 may mediate 
the innate resistance of C57BL/6 mice against progressive 
leishmaniasis. Indeed, challenge of 3-wk infected mice with 
LPS resulted in the greater appearance of circulating IL-12 
in C57BL/6 mice (400 U/ml) compared with BALB/c mice 
(<10 U/ml), as measured by bioassay and confirmed by cap- 
ture of 256 U/ml (or 1.4 ng/ml) of the C57BL/6 activity 
by specific anti-mouse IL-12 mAb combined with bioassay 
(11). IL-12 was not detected in the absence of a LPS chal- 
lenge or in the serum of uninfected mice receiving LPS (~ 10 
U/ml). These results  are consistent with a greater capacity 
for IL-12 release as a result of leishmaniasis in resistant mice 
and were prompted by parallel observations in C57BL/6 and 
BALB/c mice infected with Bacillus-Calmette-Guerin (15). 
Because strongly neutralizing antibodies against murine IL- 
l2 are currently unavailable, we could not confirm if endoge- 
nous IL-12 plays a role in C57BL/6 resistance. Furthermore, 
although IL-12 p35 and p40 mRNA expression was increased 
in C57BL/6 mice during infection, the p40 and p35 tran- 
scripts were associated with different cell populations in the 
draining lymph nodes (data not shown). Because synthesis 
of functional IL-12 requires that both subunits be expressed 
in the same cell, these Northern blot data did not provide 
easily interpretable conclusions about the in vivo synthesis 
of IL-12 in response to infection. Further studies are neces- 
sary to determine the cellular origin and kinetics of IL-12 
release during leishmaniasis. 
Our  data  show  that  rMulL-12  durably  alters  CD4 + 
subset differentiation when given in the critical  first week 
of infection. Although cure was undoubtedly assisted by the 
increased Thl activity in the draining lymph nodes, the rela- 
tively greater negative effect on IL-4 production suggests that 
considerable benefit may have been provided through removal 
of a known antagonist of IFN-7-activated macrophage leish- 
manial killing (16, 17). The dependence of CD4 + subset 
outcomes, particularly that  of Th2 cells, on IFN-3,  after 
rMulL-12 therapy is consistent with studies showing that 
IFN-3, is required for both cure and unipolar Thl cell re- 
sponses in infected C57BL/6 mice (12, 18). However, infected 
BALB/c mice cannot be cured by treatment with rMulFN-~/ 
alone (7), and this suggests that IL-12 may provide separate 
inductive signals necessary for the appearance of curative T 
cell responses. 
The ability of rMulL-12 to cure leishmaniasis in normally 
susceptible BALB/c mice strongly supports a unique role for 
this cytokine in the induction of protective immunity against 
intracellular parasitic infection. This is the first instance where 
any recombinant cytokine has been curative for infection with 
L. major (6). Further studies will be required to link differ- 
1508  Interleukin 12 Cures Murine Leishmaniasis ences in the production of IL-12 during leishmaniasis to the 
heterogeneity of disease outcomes observed in humans and 
inbred mice (2,  19), and to define the role of IL-12 in the 
pathogenesis of inflammatory and allergic disorders similarly 
mediated by disparate  CD4 + T  cell responses. 
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